Epruvy (previously Ranibizumab Midas)

Ranibizumab Midas is a medicine used to treat adults with certain sight problems caused by damage to the retina (the light-sensing layer at the back of the eye), and more specifically its central region, known as the macula. The macula provides the vision needed to see detail for everyday tasks such as driving, reading and recognising faces. Ranibizumab Midas is used to treat: - ‘wet’ form of age-related macular degeneration (AMD). The wet form of AMD is caused by choroidal neovascularisation (abnormal growth of blood vessels beneath the retina, which may leak fluid and blood and cause swelling); - macular oedema (swelling of the macula) caused by diabetes or by occlusion (blockage) of the veins behind the retina; - proliferative diabetic retinopathy (growth of abnormal tiny blood vessels in the eye, associated with diabetes); - other sight problems associated with choroidal neovascularisation. Ranibizumab Midas contains the active substance ranibizumab and is a biological medicine. It is a ‘biosimilar medicine’; this means that Ranibizumab Midas is highly similar to another biological medicine (the ‘reference medicine’) that is already authorised in the EU. The reference medicine for Ranibizumab Midas is Lucentis. For more information on biosimilar medicines, see [here](https://www.ema.europa.eu/en/human-regulatory/overview/biosimilar-medicines).